The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Plants respond to injury by signalling that damage has occurred, by secreting materials to seal off the damaged area, by producing antimicrobials to limit the spread of pathogens, and in some woody plants by regrowing over the wound.
Nitro cold brew is a variation of cold brew coffee that adds nitrogen gas to create a smooth texture, delivering the nitrogenated coffee from a nitrogen beer tap system. It was introduced in the early 2010s.
=== Metabolism === Among the many metabolic processes in which it participates, glutathione is required for the biosynthesis of leukotrienes and prostaglandins. It plays a role in cysteine storage. Glutathione enhances the function of citrulline as part of the nitric oxide cycle. It is a cofactor and acts on glutathione peroxidase. Glutathione facilitates metabolism of xenobiotics. Glutathione S-transferase enzymes catalyze its conjugation to lipophilic xenobiotics, facilitating their excretion or further metabolism. The conjugation process is illustrated by the metabolism of N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is a reactive metabolite formed by the action of cytochrome P450 on paracetamol (acetaminophen). Glutathione conjugates to NAPQI, and the resulting ensemble is excreted. As a result of this reaction, cellular glutathione concentration tends to be depleted in the presence of acetaminophen.
=== Agricultural and horticultural use === The agricultural and horticultural uses for chitosan, primarily for plant defense and yield increase, are based on how this glucosamine polymer influences the biochemistry and molecular biology of the plant cell. The cellular targets are the plasma membrane and nuclear chromatin. Subsequent changes occur in cell membranes, chromatin, DNA, calcium, MAP kinase, oxidative burst, reactive oxygen species, callose pathogenesis-related (PR) genes, and phytoalexins. Chitosan was first registered as an active ingredient (licensed for sale) in 1986.
Sources: en.wikipedia.org
Somalia's foreign relations are handled by the President as the head of state, the Prime Minister as the head of government, and the federal Ministry of Foreign Affairs. According to Article 54 of the national constitution, the allocation of powers and resources between the Federal Government and the Federal Republic of Somalia's constituent Federal Member States shall be negotiated and agreed upon by the Federal Government and the Federal Member States, except in matters pertaining to foreign affairs, national defence, citizenship and immigration, and monetary policy. Article 53 also stipulates that the Federal Government shall consult the Federal Member States on major issues related to international agreements, including negotiations vis-a-vis foreign trade, finance and treaties. The Federal Government maintains bilateral relations with a number of other central governments in the international community. Among these are Djibouti, Ethiopia, Egypt, the United Arab Emirates, Yemen, Turkey, Italy, the United Kingdom, Denmark, France, the United States, the People's Republic of China, Japan, Russian Federation and South Korea. Additionally, Somalia has several diplomatic missions abroad. There are likewise various foreign embassies and consulates based in the capital Mogadishu and elsewhere in the country. Somalia is also a member of many international organisations, such as the United Nations, African Union and Arab League. It was a founding member of the Organisation of Islamic Cooperation in 1969.
=== Preparation === Harvested chilies may be used fresh, or dried, typically on the ground in hot countries, to make a variety of products. Drying enables chilies grown in temperate regions to be used in winter. For home use, chilies can be dried by threading them with cotton and hanging them up in a warm dry place to dry.
== Advantages == MIKES, as the name implies, is used for kinetic energy spectrometery. This means that certain criteria are needed to accomplish this. One such feature of MIKES is that it has high kinetic energy resolution and good angular resolution. This is due to the fact that MIKES has low accelerating voltage, around 3 kilo-volts. Another feature is that it has good differential pumping between the various regions of the instrument. In addition, MIKES has multiple systems for bringing in and/or overseeing collision gases or vapors and the ability to vary slit height and width. This prevents favoritism when determining kinetic energy distributions. Although common now, back in the 1970s, MIKES had a great computer compatibility that allowed for readily obtainable molecular structures.
Sources: en.wikipedia.org
=== Structure === The nano-sized structure of nanocapsules allows permeating through basal membranes, which makes them effective carriers of medicine in biological systems. The specific processing of nanocapsules gives them unique properties in how they release drugs in certain situations. Generally, there are three physico-chemical release mechanisms that are used to release the drug or medicine from the polymeric shell of the nanocapsule.
=== Stress === A high proportion of patients with an acute stress such as stroke or myocardial infarction may develop hyperglycemia, even in the absence of a diagnosis of diabetes. (Or perhaps stroke or myocardial infarction was caused by hyperglycemia and undiagnosed diabetes.) Human and animal studies suggest that this is not benign, and that stress-induced hyperglycemia is associated with a high risk of mortality after both stroke and myocardial infarction. Somatostatinomas and aldosteronoma-induced hypokalemia can cause hyperglycemia but usually disappears after the removal of the tumour. Stress causes hyperglycaemia via several mechanisms, including through metabolic and hormonal changes, and via increased proinflammatory cytokines that interrupt carbohydrate metabolism, leading to excessive glucose production and reduced uptake in tissues. Hormones such as the growth hormone, glucagon, cortisol, and catecholamines, can cause hyperglycemia when they are present in the body in excess amounts.
Actin plays a particularly prominent role in muscle cells, which consist largely of repeated bundles of actin and myosin II. Each repeated unit – called a sarcomere – consists of two sets of oppositely oriented F-actin strands ("thin filaments"), interlaced with bundles of myosin ("thick filaments"). The two sets of actin strands are oriented with their (+) ends embedded in either end of the sarcomere in delimiting structures called Z-disks. The myosin fibrils are in the middle between the sets of actin filaments, with strands facing in both directions. When the muscle contracts, the myosin threads move along the actin filaments towards the (+) end, pulling the ends of the sarcomere together and shortening it by around 70% of its length. In order to move along the actin thread, myosin must hydrolyze ATP; thus ATP serves as the energy source for muscle contraction. At times of rest, the proteins tropomyosin and troponin bind to the actin filaments, preventing the attachment of myosin. When an activation signal (i.e. an action potential) arrives at the muscle fiber, it triggers the release of Ca2+ from the sarcoplasmic reticulum into the cytosol. The resulting spike in cytosolic calcium rapidly releases tropomyosin and troponin from the actin thread, allowing myosin to bind, and muscle contraction to begin.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.